Peptide Therapeutic

Peptide Therapeutic

Peptide therapeutics are drugs built from short amino acid chains, usually 2 to 50 units long, designed to act on specific targets such as cell surface receptors, enzymes or contact points between proteins. Compared with small-molecule drugs, peptides can be very specific and potent, because they can copy the three-dimensional binding shape of the body’s own hormones and signaling molecules. The field has grown fast: more than 80 peptide drugs are approved worldwide, and hundreds more are in clinical development in areas such as metabolic disease, cancer and immunology.

A key challenge is that natural peptides are unstable. Enzymes in the gut and blood break them down quickly. To get around this, chemists swap in non-natural amino acids, modify the peptide backbone, attach fat chains that bind albumin, or add PEG groups (PEGylation) to keep the drug in the blood longer. These changes have made long-acting forms possible that can be given once a week or even less often, which makes treatment far easier to stick with than earlier peptide drugs that needed several injections a day.

Clinical Relevance to Retatrutide

Retatrutide is an engineered peptide drug, modified to act in a balanced way on three receptor targets (GLP-1, GIP and glucagon) in a single molecule. It carries a fatty acid side chain that binds to albumin in the blood, extending its half-life enough for a once-weekly injection under the skin. Keeping drug levels effective across the whole week depends on this, and it reflects decades of progress in peptide engineering for incretin drugs.